Discovery of Novel Thiazolidinedione-Derivatives with Multi-Modal Antidiabetic Activities In Vitro and In Silico.

Charles Arineitwe, Ogunyemi Oderinlo, Matshawandile Tukulula, Setshaba Khanye, Andile Khathi, Ntethelelo Sibiya

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Design and evaluation of novel thiazolidinedione-oxadiazole derivatives as potent α-amylase inhibitors for antidiabetic therapy.Journal of computer-aided molecular design · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Charles ArineitwePharmacology Division, Rhodes University, Grahamstown 6140, South Africa.

Ogunyemi OderinloDepartment of Chemistry, Faculty of Science, Federal University, Otuoke Bayelsa 562103, Nigeria.ORCID 0000-0002-6180-5502

Matshawandile TukululaSchool of Chemistry and Physics, College of Agriculture, Engineering Sciences, University of KwaZulu-Natal, Durban 4000, South Africa.ORCID 0000-0002-1844-3614

Setshaba KhanyePharmaceutical Chemistry Division, Faculty of Pharmacy, Rhodes University, Makhanda 6140, South Africa.ORCID 0000-0003-0725-5738

Andile KhathiSchool of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa.ORCID 0000-0002-2246-0038

Ntethelelo SibiyaPharmacology Division, Rhodes University, Grahamstown 6140, South Africa.

Funding

National Research Foundation 123375Research Development Capacity grant RCDG: 05

6 · The paper itself

Abstract

Diabetes mellitus (DM) and related complications continue to exert a significant burden on health care systems globally. Although conventional pharmacological therapies are beneficial in the management of this metabolic condition, it is still necessary to seek novel potential molecules for its management. On this basis, we have synthesised and evaluated the anti-diabetic properties of four novel thiazolidinedione (TZD)-derivatives. The TZD derivatives were synthesised through the pharmacophore hybridisation strategy based on

Indexed as

Hypoglycemic AgentsThiazolidinedionesGlucoseMolecular Docking SimulationPPAR gammaRosiglitazone2,4-thiazolidinedioneGlucoseHypoglycemic AgentsPPAR gammaRosiglitazoneThiazolidinedionesdiabetes mellituspharmacological screeningsynthesistherapeutic targetsthiazolidinedione-derivatives

Identifiers

PMID36769344

DOI10.3390/ijms24033024

PMCPMC9917550

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.